This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

For Inflectra® (infliximab) Prescribing Information for Great Britain click here.
Adverse event reporting information can be found at the bottom of the page.

NOR-SWITCH safety

NOR-SWITCH was a randomised, double-blind, non-inferiority parallel-group study that compared the effect of switching from Remicade®† to Inflectra/CT-P13* (infliximab) in 481 patients across all indications.§1

There was a similar adverse event profile in stable patients switching from Remicade®† to CT-P13*, compared with those remaining on Remicade®.§1  

Treatment-emergent adverse events1

Safety population. Data are number of events/number of patients (%).
​​​​​​​Created from Jørgensen KK, et al. 2017.

Explore more

Crohn’s disease safety

Learn about the safety profile of Inflectra in patients with Crohn’s disease

Learn more

Optimising treatment with Inflectra

Learn more about TDM and biomarkers

Find out more
†Remicade® is a registered trademark of MSD.
*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
§Only single one-way switching from Remicade® to CT-P13* was examined in this study. The NOR-SWITCH trial included only patients on Remicade® and CT-P13*; its findings do not support that any other biosimilars of infliximab can achieve the same result.
References
  1. Jørgensen KK, et al. Lancet 2017. 389:2304–2316.
PP-IFA-GBR-0507. September 2021

Quick Links

  • GONCZI L et al

  • Study 3.4

  • NOR-SWITCH safety

  • NOR-SWITCH efficacy

  • PROSIT-BIO safety

  • PROSIT-BIO efficacy

  • PROSIT-BIO study design

  • Switch studies

  • Paediatric studies

  • Induction & Maintenance

  • Inflammatory bowel disease

Learn about the mechanism of action of Infliximab.

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Find out more

** This is an optional area where footnotes can live.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?